APUS Key Statistics, Chart & Performance
The current stock price of APUS is 1.78 USD. In the past month the price decreased by -18.72%.
APUS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About APUS
Company Profile
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.
Company Info
APIMEDS PHARMACEUTICALS US I
100 Matawan Road, Suite 325
Matawan NEW JERSEY US
Employees: 2
Phone: 18482015010
APIMEDS PHARMACEUTICALS US I / APUS FAQ
What does APIMEDS PHARMACEUTICALS US I do?
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.
What is the current price of APUS stock?
The current stock price of APUS is 1.78 USD. The price increased by 1.14% in the last trading session.
Does APUS stock pay dividends?
APUS does not pay a dividend.
What is the ChartMill rating of APIMEDS PHARMACEUTICALS US I stock?
APUS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy APUS stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on APUS.
What is APIMEDS PHARMACEUTICALS US I worth?
APIMEDS PHARMACEUTICALS US I (APUS) has a market capitalization of 22.39M USD. This makes APUS a Nano Cap stock.
APUS Technical Analysis
APUS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to APUS. APUS has a great financial health rating, but its profitability evaluates not so good.
APUS Financial Highlights
Over the last trailing twelve months APUS reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS decreased by -78.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.18% | ||
| ROE | -14.27% | ||
| Debt/Equity | 0 |